Emergency medicament dose control
Inventors
Rosinko, Michael J. • EL-KHATIB, Firas H. • DAMIANO, Edward R. • Lim, David Chi-Wai • Raskin, Edward B.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12465686-B2
Publication Date
2025-11-11
Expiration Date
Abstract
Automated glucose level control system that provide therapy to a subject, such as glucose control, are disclosed. The system generates dose control signals using control algorithms configured to autonomously determine doses of insulin to be infused into a subject. When the system determines that an initial dose control signal does not indicate health-appropriate therapy, the system can modify a manual therapy instruction and transmit an emergency dose control signal to the medicament pump. Disclosed systems and devices can track insulin therapy administered to the subject over a tracking period, including storing an indication of the autonomously determined doses of insulin delivered to the subject. The system can generate a backup therapy protocol with insulin therapy instructions based at least in part on the insulin therapy administered to the subject over the tracking period.
Core Innovation
The glucose level control system receives a manual therapy instruction and, based on that instruction, transmits an initial dose control signal to a pump controller of a medicament pump. Upon receiving the subject's glucose level via a data interface, the system determines whether the initial dose control signal indicates health-appropriate therapy. When the initial signal does not indicate health-appropriate therapy, the system generates an emergency dose control signal commanding administration of modified glucose control therapy.
Based on the emergency dose control signal, the system modifies the manual therapy instruction and transmits the emergency dose control signal to the pump controller, accompanied by graphic user interface updating and visual displays. In addition, the system provides capabilities for tracking therapy, generating backup injection or pump protocols from logged therapy, and adaptively refining glucose-control parameters, including insulin pharmacokinetic model Tmax, using glucose trends and therapy-delivery data.
Claims Coverage
The claims identify one independent claim directed to a glucose level control system, comprising four inventive features.
Manual therapy instruction reception and initial dose control signal transmission
The system receives a manual therapy instruction via a manual therapy control interface and, based on that instruction, transmits an initial dose control signal to a pump controller of a medicament pump.
Assessment of health-appropriate therapy
The system receives the subject's glucose level via a data interface and determines, based at least in part on that glucose level, that the initial dose control signal does not indicate health-appropriate therapy.
Emergency dose control signal generation for modified therapy
Based on the determination that the initial dose control signal does not indicate health-appropriate therapy, the system generates an emergency dose control signal commanding administration of modified glucose control therapy to the subject via the medicament pump.
Instruction modification and visual display updating
Based on the emergency dose control signal, the system modifies the manual therapy instruction and transmits the emergency dose control signal to the pump controller along with graphic user interface updating and visual displays.
The independent claim covers receiving a manual therapy instruction and glucose level, evaluating whether the initial dose control signal indicates health-appropriate therapy, and, if it does not, modifying the manual therapy instruction and transmitting an emergency dose control signal to the pump controller along with visual updates.
Stated Advantages
Not explicitly described in patent.
Documented Applications
A glucose level control system configured to command administration of modified glucose control therapy to a subject via a medicament pump.
Estimating carbohydrate therapy avoided or replaced by counter-regulatory dosing in glucose-control system embodiments.
Generating backup injection or pump protocols from logged therapy.
Adaptively refining glucose-control parameters, including insulin pharmacokinetic model Tmax, using therapy and glucose data.
An ambulatory glucose-management device and therapy-control interfaces, as well as glucose-therapy control-parameter refinement using therapy effects, glucose levels, glucose thresholds, assessments of improvement, and hypoglycemia probability.
Interested in licensing this patent?